VBI Vaccines Inc.
VBIV · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $9 | $1 | $1 | $1 |
| % Growth | 702.4% | 71.5% | -40.5% | – |
| Cost of Goods Sold | $14 | $11 | $11 | $9 |
| Gross Profit | -$6 | -$10 | -$10 | -$8 |
| % Margin | -67% | -942.1% | -1,606.8% | -764.1% |
| R&D Expenses | $9 | $16 | $20 | $15 |
| G&A Expenses | $42 | $56 | $38 | $21 |
| SG&A Expenses | $40 | $56 | $38 | $21 |
| Sales & Mktg Exp. | -$2 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $49 | $72 | $58 | $36 |
| Operating Income | -$55 | -$82 | -$68 | -$44 |
| % Margin | -637.1% | -7,561.9% | -10,781.6% | -4,110.9% |
| Other Income/Exp. Net | -$38 | -$31 | -$2 | -$3 |
| Pre-Tax Income | -$93 | -$113 | -$70 | -$46 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$93 | -$141 | -$73 | -$47 |
| % Margin | -1,069.3% | -13,026.9% | -11,513.5% | -4,456.7% |
| EPS | -5.96 | -16.37 | -8.55 | -6.5 |
| % Growth | 63.6% | -91.5% | -31.5% | – |
| EPS Diluted | -5.96 | -16.37 | -8.55 | -6.5 |
| Weighted Avg Shares Out | 16 | 9 | 8 | 7 |
| Weighted Avg Shares Out Dil | 16 | 9 | 8 | 7 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $1 | $0 | $1 |
| Interest Expense | $8 | $5 | $5 | $3 |
| Depreciation & Amortization | $2 | $2 | $2 | $2 |
| EBITDA | -$83 | -$106 | -$63 | -$41 |
| % Margin | -953.5% | -9,798.5% | -9,954.7% | -3,888.5% |